VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 24.1% in February

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 2,200 shares, a decline of 24.1% from the January 31st total of 2,900 shares. Based on an average daily trading volume, of 11,700 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC raised its stake in VanEck Biotech ETF by 401.7% during the third quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock worth $1,481,000 after buying an additional 6,684 shares during the last quarter. Flagship Harbor Advisors LLC grew its holdings in VanEck Biotech ETF by 12.1% during the 4th quarter. Flagship Harbor Advisors LLC now owns 1,984 shares of the company’s stock worth $311,000 after acquiring an additional 214 shares during the period. Janney Montgomery Scott LLC bought a new position in shares of VanEck Biotech ETF in the 4th quarter worth about $481,000. Kovitz Investment Group Partners LLC lifted its stake in shares of VanEck Biotech ETF by 4.6% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock valued at $565,000 after purchasing an additional 141 shares during the period. Finally, Tyler Stone Wealth Management boosted its position in shares of VanEck Biotech ETF by 79.5% during the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock valued at $261,000 after purchasing an additional 652 shares in the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

Shares of BBH opened at $162.53 on Tuesday. The business has a 50-day moving average of $161.60 and a 200-day moving average of $168.93. The company has a market capitalization of $390.07 million, a price-to-earnings ratio of 30.97 and a beta of 0.77. VanEck Biotech ETF has a 1 year low of $151.35 and a 1 year high of $183.64.

VanEck Biotech ETF Announces Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were issued a dividend of $1.2517 per share. The ex-dividend date of this dividend was Monday, December 23rd.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.